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Clinical and Molecular Findings in Osteoporosis-Pseudoglioma Syndrome
Minrong Ai, Shauna Heeger, Cynthia F. Bartels, Deborah K. Schelling,
and the Osteoporosis-Pseudoglioma Collaborative Group*
Department of Genetics and Center for Human Genetics, Case School of Medicine and University Hospitals of Cleveland, Cleveland
Mutations in the low-density lipoprotein receptor–related protein 5 gene (LRP5) cause autosomal recessive osteo-
porosis-pseudoglioma syndrome (OPPG). We sequenced the coding exons of LRP5 in 37 probands suspected of
having OPPG on the basis of the co-occurrence of severe congenital or childhood-onset visual impairment with
bone fragility or osteoporosis recognized by young adulthood. We found two putative mutant alleles in 26 probands,
only one mutant allele in 4 probands, and no mutant alleles in 7 probands. Looking for digenic inheritance, we
sequenced the genes encoding the functionally related receptor LRP6, an LRP5 coreceptor FZD4, and an LRP5
ligand, NDP, in the four probands with one mutant allele, and, looking for locus heterogeneity, we sequenced FZD4
and NDP in the seven probands with no mutations, but we found no additional mutations. When we compared
clinical features between probands with and without LRP5 mutations, we found no difference in the severity of
skeletal disease, prevalence of cognitive impairment, or family history of consanguinity. However, four of the seven
probands without detectable mutations had eye pathology that differed from pathology previously described for
OPPG. Since many LRP5 mutations are missense changes, to differentiate between a disease-causing mutation and
a benign variant, we measured the ability of wild-type and mutant LRP5 to transduce Wnt and Norrin signal ex
vivo. Each of the seven OPPG mutations tested, had reduced signal transduction compared with wild-type mu-
tations. These results indicate that early bilateral vitreoretinal eye pathology coupled with skeletal fragility is a
strong predictor of LRP5 mutation and that mutations in LRP5 cause OPPG by impairing Wnt and Norrin signal
transduction.
Introduction
Osteoporosis-pseudoglioma syndrome (OPPG [MIM
259770]) is an autosomal recessive disorder generally
characterized by congenital or infancy-onset visual loss
and skeletal fragility recognized during childhood. Mu-
tations in the low-density lipoprotein receptor–related
protein 5 (encoded by LRP5) cause OPPG (Gong et al.
2001). OPPG is a rare disorder. With the assumption of
an estimated population incidence of 1 per 2,000,000
and a carrier frequency of 1 per 700, ∼380,000 U.S.
citizens are predicted to be carriers of deleterious LRP5
mutations. Heterozygous carriers of OPPG-causing mu-
tations have reduced bone-mineral density (BMD) com-
pared with age- and sex-matched controls (Gong et al.
2001; Lev et al. 2003), and LRP5 mutations have been
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found among individuals with “idiopathic” osteoporosis
and/or skeletal fragility (Hartikka et al. 2005). Popula-
tion-based studies suggest that common variants ofLRP5
contribute to the normal population variation in BMD
(Ferrari et al. 2004; Mizuguchi et al. 2004; Bollerslev et
al. 2005). Two other phenotypes have been attributed
to a mutation in LRP5. Heterozygous missense muta-
tions in the receptor’s ﬁrst six-bladed propeller domain
can cause autosomal dominant disorders of high bone
mass (HBM), in which BMD is several SDs above the
mean (Boyden et al. 2002; Little et al. 2002; Van Wes-
enbeeck et al. 2003). These mutations may cause a gain
of function in the receptor by altering a binding site for
the receptor’s endogenous inhibitors (Boyden et al. 2002;
Ai et al. 2005). Heterozygous and homozygous muta-
tions have also been described in some patients with the
eye disease familial exudative vitreoretinopathy (FEVR)
(Jiao et al. 2004; Toomes et al. 2004; Qin et al. 2005),
a locus heterogeneous disorder that can also be caused
by mutations in a secreted ligand, Norrin (NDP) (Chen
et al. 1993), and an LRP5 coreceptor, Frizzled 4 (FZD4)
(Robitaille et al. 2002).
LRP5 is a member of the low-density lipoprotein re-
ceptor superfamily of cell-surface receptors. Similar to
the prototype family member LDLR, LRP5 has been im-
plicated in plasma lipid homeostasis in mice (Fujino et
al. 2003; Magoori et al. 2003). However, the relevance
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Figure 1 Disease-associated missense mutations in LRP5. A, Schematic depiction of LRP5 protein and the sites of missense amino acid
substitutions that have been associated with OPPG. Homozygous mutations in patients with OPPG are noted in bold above the protein.
Heterozygous mutations in patients with OPPG are shown below the protein. Two missense mutations that occur in cis on a single allele are
marked with an asterisk (*). Missense mutations that are associated with autosomal dominant FEVR are shown in italics, and mutations
associated with autosomal recessive FEVR are in bold italics. All underlined mutations were tested ex vivo. B, Single-letter amino acid ClustalW
alignments of residues surrounding the 20 OPPG-associated missense mutations for LRP5, LRP6, and arrow. The amino acid residues altered
by the missense mutations are shaded in the species in which the residue is evolutionarily conserved. The seven putative OPPG-causingmutations
that were tested ex vivo are shown in the upper half of the panel.
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Figure 2 Trafﬁcking and posttranslationalmodiﬁcation ofOPPG-
LRP5 mutants in 293T cells. A, WT and OPPG-causing LRP5 con-
structs that express a myc-tagged, truncated polypeptide lacking the
transmembrane and cytoplasmic domains (LRP5N-myc) were tran-
siently transfected into 293T cells. Western-blot analyses were per-
formed to detect the recombinant protein in the conditioned medium
(“CM”) and cell lysate (“Lysate”) with use of an anti-myc antibody.
Note the relative efﬁciencies of different mutants to transit the cell and
be secreted into the conditioned medium compared with the WT pro-
tein. T390K is present in the cell lysate but is not secreted into the
conditioned medium, whereas G520V is secreted into the conditioned
medium at rates comparable to WT. Equal loading of cell lysate and
conditioned medium in each lane is demonstrated by immunodetection
of cell lysate with an anti-tubulin antibody, D-10-HRP (Santa Cruz
Biotechnology), and Coomassie staining of conditioned medium, re-
spectively. B, Western-blot analysis of conditioned medium (“CM”)
and cell lysate (“LY”) from 293T cells expressing WT or G520V
LRP5N-myc protein. Note that, when the conditioned medium was
digested with N-glycosidase (“DG”), the molecular weight of the se-
creted protein was decreased. Other OPPG-associated mutant proteins
were tested in the same assay and gave similar results (data not shown).
of this function to human plasma lipid homeostasis has
not yet been evaluated. The most important role of
LRP5 in humans is as a cell-surface signaling receptor.
LRP5 serves as a coreceptor with members of the friz-
zled family of seven-pass membrane receptors in trans-
ducing signal by two extracellular ligand classes, Norrin
and Wnts. Evidence to support LRP5 function as a Nor-
rin coreceptor derives from ex vivo cell signaling assays
(Xu et al. 2004) and the aforementioned observation
that mutations in NDP, FZD4, or LRP5 can each cause
FEVR. Evidence to support LRP5 function as a core-
ceptor in canonical Wnt signaling also derives from ex
vivo signaling assays (Tamai et al. 2000; Gong et al.
2001) and from observations of phenotypic overlap be-
tween knockout and transgenic mouse models involving
Lrp5 (Kato et al. 2002; Babij et al. 2003; Holmen et
al. 2004), its closely related family member Lrp6 (Hol-
men et al. 2004), and members of the Wnt ligand su-
perfamily (Bennett et al. 2005). Current data suggest
that the skeletal effects of LRP5 mutations result from
altered Wnt signaling and that the altered visual effects
result from altered Norrin signaling. However, this hy-
pothesis has not been deﬁnitively proven.
Most clinical descriptions of patients with OPPG were
published prior to the discovery of LRP5 (summarized
by Gong et al. [1996]). With the identiﬁcation of LRP5
as the responsible gene, it is now possible to deﬁne phe-
notypic features that are common to patients with mu-
tation-conﬁrmed OPPG, to describe the disease course
in these individuals, to correlate their phenotype with
their genotype, and to address whether OPPG exhibits
locus heterogeneity. Since there is the prediction of a large
number of OPPG carriers who are at increased risk of
osteoporosis (Gong et al. 2001), it is also important to
determine the functional consequences of speciﬁc mis-
sense variations in LRP5—in particular, whether they
interfere with Wnt and/or Norrin signaling and whether
their mechanism of mutational effect is to cause a simple
loss of function or an interfering function within the
signaling complex. We report the clinical features and
the results of mutation detection by direct sequencing
of PCR amplimers from genomic DNA in a cohort of
37 probands/families in whom OPPG was clinically sus-
pected. We also describe the functional consequences of
several missense mutations found in patients withOPPG
on LRP5 receptor trafﬁcking and on Wnt and Norrin
signal transduction, and we compare them with wild-
type (WT) protein and missense mutants that have been
associated with FEVR.
Material and Methods
Recruitment of Study Participants
Individuals clinically suspected of having OPPG were
invited to participate in the present study. Informed con-
sent was obtained from all study participants. The insti-
tutional review board at University Hospitals of Cleve-
land approved the study. All participants, or their phy-
sicians, were asked to complete a detailed questionnaire
about clinical features and disease course (the clinical
data form used in the study is accessible from the War-
man lab Web site).
Mutation Detection in LRP5, LRP6, FZD4, and NDP
by Use of Genomic DNA
Participant DNA was extracted and quantiﬁed using
standard techniques. Genomic DNA (50 ng) was ampli-
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ﬁed by PCR in 25-ml reactions by use of intronic primers
that ﬂank each exon. Primer sequences and locations
relative to the exon splice sites for the 23 LRP5 coding
exons are available on request. Standard PCR conditions
(94C for 5 min, 35 cycles of 94C for 1 min, 57C for
50 s, and 72C for 50 s, followed by a single 72C 10-
min extension) were used, with the following exceptions:
reactions for exons 1, 4, and 5 contained 10% dimethyl
sulfoxide, and the reaction for exon 21 contained 10%
enhancer solution (Invitrogen). Primer annealing tem-
peratures were 70C for exons 1 and 23 and were 60C
for exons 4, 5, and 21. Ampliﬁcation primer pairs for
exons 1 and 3–9 were designed to avoid amplifying the
LRP5 pseudogene on chromosome 22.
Amplicons were sequenced with BigDye 1.1 or 3.1
chemistry (Applied Biosystems) on an ABI 3100 or 3730
sequencer. Sequencing primers were usually the same
primers used in PCR. Internal primers were used in some
sequencing reactions. The ABI Sequence Analysis Soft-
ware (v5.1) was used, and sequence electropherograms
were also visually inspected for quality and for evidence
of heterozygous changes and were electronically aligned
with genomic sequences from human clones AC024124
and AC024123, to look for other types of mutations.
Mutations identiﬁed in each proband were conﬁrmed by
sequencing amplimers from the proband’s parents or a
sibling. For two mutations for which a relative was un-
available, the probands’ mutations were conﬁrmed by
sequencing independent amplimers, to exclude the pos-
sibility that the mutations were created during PCR. We
did not look for mutations in ethnically/geographically
matched controls, to differentiate a disease-causing mu-
tation from a low-frequency polymorphism.
In four probands for whom only one putative disease-
causing allele in LRP5was identiﬁed, the 23 coding exons
of LRP6, the two coding exons of FZD4, and the two
coding exons of NDP were also PCR ampliﬁed and se-
quenced (primers and conditions are available on request).
FZD4 and NDP were also sequenced for the seven pro-
bands for whom no LRP5 mutations were found.
Creation of Expression Constructs for LRP5
Construction of full-length human LRP5 (WT-LRP5)
and a truncated form of human LRP5 that lacks the
transmembrane and cytoplasmic domains but has a myc
and His6 epitope at the C-terminus (LRP5N-myc) have
been described elsewhere (Ai et al. 2005). Putative dis-
ease-causing missense mutations were introduced into
WT-LRP5 by site-directed mutagenesis (Quickchange
[Stratagene]). Smaller restriction fragments were subclo-
ned from the expression construct, were used as the tem-
plate for mutagenesis, were sequence veriﬁed, and were
then shuttled into the original expression vectors. For
example, the T244M mutation was introduced into a
1.3-kb EcoRI/SalI restriction fragment containing the
ﬁrst epidermal growth factor–like (EGF-like) domain,
and the S356L, T390K, G404R, D434N, G520V, and
G610R mutations were individually introduced into a
700-bp SalI/XhoI restriction fragment containing cod-
ing sequence for part of the second EGF-like domain.
FEVR-associated mutations T173M, R570Q, Y1168H,
C1361G, and E1367K were made in a similar manner.
Other expression vectors used in this study were mouse
Wnt1-v5 (Ai et al. 2005), Wnt 10b (Bennett et al. 2005),
Norrin and Frizzled 4 (Xu et al. 2004), MESD-C2 and
RAP (Hsieh et al. 2003), Topﬂash (Korinek et al. 1997),
and pRL-TK (Upstate Biotechnology).
Ex Vivo Reporter Assays for Wnt and Norrin Signal
Transduction
HEK293T cells (American Type Culture Collection),
cultured in Dulbecco’s modiﬁed essential medium con-
taining 10% fetal bovine serum, were plated at 2.5#
cells per well in 24-well plates 24 h prior to trans-510
fection. Transfection was done in serum-free media with
Lipofectamine Plus (Invitrogen), in accordance with
the manufacturer’s protocol. For Wnt-signaling assays,
DNA transfections included the following expression
constructs: Topﬂash (100 ng), pRL-TK (5 ng), MESD-
C2 (20 ng), WT-LRP5 or LRP5 constructs containing
missense mutations (30 ng), and Wnt1-v5 or Wnt10b
(100 ng). For Norrin-signaling assays, DNA transfec-
tions included the following expression constructs: Top-
ﬂash (100 ng), pRL-TK (5 ng), MESD-C2 (20 ng), WT-
LRP5 or LRP5 constructs containingmissensemutations
(30 ng), Fzd4 (50 ng), and Norrin (50 ng). To assure
that equal amounts of DNA were transfected in each
experiment, pcDNA3.1-LacZ (Invitrogen) was added to
make 255 ng the total amount of DNA per transfection.
Cells were lysed 30 h after transfection. Fireﬂy luciferase
activity from the Topﬂash reporter was measured using
a dual Luciferase assay kit (Promega) in a luminometer
(Molecular Devices). Renilla luciferase activity from
pRL-TK was measured, as an internal control for trans-
fection efﬁciency. Each assay was performed in triplicate.
Data from single experiments are reported in the “Re-
sults” section, but each experiment was performed three
times with consistently reproducible results.
Assay to Assess Trafﬁcking of WT and OPPG LRP5
Constructs That Lack the Transmembrane and
Cytoplasmic Domains
WT-LRP5N-myc or LRP5N-myc constructs that con-
tained OPPG missense mutations were used. These con-
structs lack the transmembrane and cytoplasmic domain
and should be secreted into the conditioned medium of
expressing cells if properly trafﬁcked. HEK293T cells
were cultured as described above. Cells were plated at
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cells per well in six-well culture plates 24 h prior55# 10
to transfection. Each well was transfected with LRP5N-
myc (200 ng), MESD-C2 (200 ng), and RAP (200 ng),
with use of Lipofectamine Plus, and was maintained in
1 ml of serum-free medium. LRP5N-myc protein was
recovered from the medium after 48 h and from the cell
lysate, by scraping the cell layer after the addition of 1
ml RIPA buffer (50 mM Tris; pH 8; 150 mM NaCl; 1%
NP-40; 0.5% deoxycholate; 0.1% sodium dodecyl sul-
fate). Twenty microliters of conditioned medium or cell
lysate were mixed with 5 ml of 5# SDS-PAGE–loading
buffer, were subjected to reducing SDS-PAGE, and were
detected by the monoclonal anti-myc antibody 9E10
(Santa Cruz Biotech). To demonstrate that the secreted
forms of LRP5 are posttranslationallymodiﬁed,wemixed
17.5 ml of LRP5N-myc that contained conditioned me-
dium with 1 ml Tris (1 M; pH 8.0), 1 ml b-mercaptoeth-
anol, and 0.5 ml SDS (10%) and heated at 99C for 5
min. We then added 25 ml water, 5 ml NP-40 (6%), and
5 ml N-glycosidase F (1 unit/ml) (Roche) and incubated
overnight at room temperature. A control reaction was
performed by adding 5 ml water instead of 5 ml N-glyco-
sidase. The control and N-glycosidase digested samples
were mixed with 25 ml 4# SDS-PAGE loading buffer,
and 25 ml were subjected to reducing SDS-PAGE and
were detected using the anti-myc antibody.
Results
LRP5 Mutations in Patients Suspected to Have OPPG
Probands from 37 families were suspected of having
OPPG (table 1). PCR ampliﬁcation and direct sequenc-
ing of amplimers for all LRP5 coding exons led to the
identiﬁcation of 11 nonsense, 11 frameshift, 2 splice-
site, and 20 missense mutations, all of whichwe assumed
were disease causing (table 1 and ﬁg. 1A). Several other
missense mutations were identiﬁed that have an appre-
ciable frequency in unaffected controls and were not con-
sidered to be disease causing (data not shown). Of the
37 probands, 12 were homozygous for the disease-caus-
ing mutations, and 14 of the 37 were compound het-
erozygous for two disease-causing mutations. A single
heterozygous mutation was detected in 4 of the 37 pro-
bands; these mutations were unlikely to cause OPPG via
a dominant mechanism, since they were also found in
an asymptomatic carrier parent or sibling. Of the 37
probands, 7 had no identiﬁed mutant LRP5 alleles.
LRP5 has a closely related paralog, LRP6, which also
serves as a Wnt receptor. Mice completely lacking Lrp6
are nonviable (Pinson et al. 2000); mice doubly hetero-
zygous for mutations in Lrp5 and Lrp6 have low bone
mass (Holmen et al. 2004). Therefore, we sequenced
LRP6 in the four probands with OPPG for whom we
could detect only a single mutant LRP5 allele, to look
for digenic inheritance; we found no LRP6 mutations.
We did not sequence LRP6 in the seven probands with
no detected LRP5 mutation, given the embryonic le-
thality in the Lrp6 homozygous mutant mice and the
lack of reported eye or severe skeletal phenotypes in the
Lrp6 heterozygous mice. Frizzled 4 and LRP5 act as
coreceptors for Norrin, and mutations in either LRP5
or FZD4 have been found to cause FEVR (Toomes et
al. 2004; Xu et al. 2004; Qin et al. 2005). Therefore,
we also sequenced FZD4 and NDP in the four probands
with single LRP5 mutations and in the seven probands
who had no identiﬁed LRP5 mutations. No FZD4 or
NDP mutations were found.
Clinical Characteristics in Probands With and Without
LRP5 Mutations
Congenital, childhood-onset, or childhood-recognized
ocular disease was reported for all 30 probands with
identiﬁed LRP5 mutations. The severity of ocular dis-
ease in patients for whom original ophthalmologic re-
cords were available ranged from phthisis bulbi to less-
severe vitreoretinal ﬁndings, such as persistent hyper-
plasia of the primary vitreous (PHPV), congenital retinal
folds, and exudative retinopathy. The majority of pro-
bands with mutations were congenitally blind in both
eyes; some were congenitally blind in one eye and vi-
sually impaired in the other or were moderately visually
impaired in both eyes. Most adult probands with LRP5
mutations—and their affected adult siblings—were blind
by age 15 years, and all were blind by age 25 years.
Four of the seven probands without LRP5 mutations had
ocular defects that had not been previously described in
OPPG, including isolated cataract, retinal coloboma, Pe-
ters anomaly, and unilateral eye involvement. The male:
female ratio is 3:2 in probands with LRP5 mutations
and 6:1 in probands without identiﬁed mutations. It
remains possible that mutation in an X-linked gene, such
asNDP,may be responsible for some instances of disease
in these probands. However, we did not ﬁnd an NDP
coding-sequence mutation in any of the patients, and os-
teoporosis and skeletal fragility have not been described
in males with Norrie disease.
Skeletal disease was apparent by adolescence in 29
of 30 probands with LRP5 mutations and in nearly all
affected siblings. One proband (family OP346) has an
affected sibling in whom skeletal disease was recognized
in his 20s (table 1). Another proband and his sibling (fam-
ily OP502) were both found to be osteoporotic in their
20s (table 1). Among all patients with LRP5 mutations,
the skeletal disease was characterized by fractures and/
or radiologically determined severe osteoporosis. Impor-
tantly, skeletal disease was recognized during the ﬁrst 2
years of life in fewer than half of the probands with
identiﬁed mutations. In several asymptomatic infants and
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toddlers, osteoporosis or vertebral compressions were
found incidentally when radiographs were obtained for
other reasons (e.g., suspected pneumonia or constipa-
tion). We observed no consistent difference in clinical
and radiographic skeletal features between probands for
whom LRP5 mutations were and were not found.
Cognitive impairment, independent of visual impair-
ment, was reported for 8 of 30 probands with identiﬁed
mutations. There were no signiﬁcant differences in the
rates of cognitive impairment between probands with ho-
mozygous (4 of 12 probands), compound heterozygous
(2 of 14 probands), or single identiﬁed (2 of 4 probands)
LRP5 mutations. Three of seven probands without iden-
tiﬁed mutations were also reported to be cognitively
impaired.
Functional Analysis of LRP5 Receptors with Missense
Mutations
We hypothesized that most nonsense and frameshift
mutations would result in nonsense-mediatedmRNAde-
cay or would produce truncated proteins that would be
improperly trafﬁcked within the cell. The consequences
of missense mutations, which accounted for 20 of the
44 putative disease-causing mutations, were less clear.
Alignment of the amino acid residues affected by the
missense mutations against LRP5 sequence frommouse,
rat, and Xenopus laevis, LRP6 sequence from human
and mouse, and arrow sequence from Drosophila me-
lanogaster demonstrated complete conservation of these
residues within LRP5 orthologs and near-complete con-
servation within LRP6 across vertebrates and arrow in
fruit ﬂy (ﬁg. 1B).
Since conservation can suggest but neither prove cau-
sality of a missense change nor predict the precise mech-
anism by which a missense change will exert an effect,
we studied several of the mutant proteins in transiently
transfected 293T cells, to determine their ability to trafﬁc
through the cell and to transduceWnt andNorrin signal.
We expressed a myc-epitope–tagged version of LRP5 that
lacks the transmembrane and cytoplasmic domains and
should be secreted into the conditioned medium when
normally trafﬁcked. The version of this construct that
contained the WT sequence was able to trafﬁc through
the cell, be posttranslationally modiﬁed by N-linked gly-
cosylation, and be secreted (ﬁg. 2).We then studied seven
different mutant proteins whose missense mutations
affect the ﬁrst or second six-bladed propeller domains
within the protein. One mutant, T390K, was expressed
within the cell but was unable to trafﬁc normally. Several
other mutants—T244M, G404R, D434N, and G610R—
appeared to trafﬁc less well than did the WT protein.
Twomutants, S356L andG520V, appeared to trafﬁc com-
parably to the WT protein (ﬁg. 2A). All secreted OPPG
mutant proteins appeared to be posttranslationallymod-
iﬁed, similar to WT LRP5 (ﬁg. 2B and data not shown).
To assess the effect of these mutations on signal trans-
duction, we coexpressed full-length, untaggedWTLRP5
(or full-length untagged mutant LRP5) with Wnt ligand
(or Norrin ligand) and measured b-catenin–mediated
signaling, using the Topﬂash reporter assay (white bars
in ﬁg. 3A and 3B). WT-LRP5 was able to transduceWnt
signal, as indicated by the large fold increase in Topﬂash
reporter activity. However, the mutant LRP5 receptors
T244M, S356L, T390K, and G520V were unable to
transduce Wnt1 or Wnt10b signal. The mutants G404R
and D434N had !50% the activity, and the mutant
G610R had 60% the activity of WT-LRP5. The pheno-
type of the probands with these latter three mutations
was not clinically milder than that of probands with
other LRP5 mutations; each was blind and had severe
skeletal disease.
Carriers of OPPG mutations often have signiﬁcantly
reduced BMD. Furthermore, some LRP5 mutations that
cause FEVR appear to act in a dominant manner. There-
fore, we coexpressed WT and mutant LRP5, to deter-
mine whether the heterozygote phenotype of LRP5 mu-
tations was likely to be due to functional haploinsufﬁ-
ciency or a dominant negative effect. When coexpressed
with WT LRP5, none of the mutant proteins interfered
with WT Wnt signal transduction (gray bars in ﬁg. 3A
and 3B). This would argue against a dominant negative
effect for these mutations on Wnt signaling.
We also assessed the effects of the LRP5 mutations
on Norrin signaling. Norrin also activates the b-catenin–
mediated signaling pathway, for which the Topﬂash re-
porter assay is a useful readout (Xu et al. 2004). Each
of the LRP5 mutants, including those that appear to
trafﬁc normally through the cell, had a signiﬁcantly re-
duced ability to transduce Norrin signal (ﬁg. 3C). This
result is consistent with the hypothesis that visual loss
in patients with OPPG results from defective Norrin sig-
naling, although this result does not preclude defective
Wnt signaling from also affecting eye development.
Three LRP5 missense mutations have been identiﬁed
in patients with autosomal recessive FEVR who were not
reported to have skeletal involvement. We tested two of
these mutants, along with three missense mutants that
have been associated with dominantly inherited FEVR,
for their ability to transduce Wnt and Norrin signal
(ﬁg. 4). One dominant mutant, Y1168H, was unable to
transduce Wnt or Norrin signal. One recessive mutant,
R570Q, had signiﬁcantly reducedWnt andNorrin signal
transduction, and one dominant mutant, C1361G, had
mildly reduced Wnt and Norrin signal transduction.
However, the remaining dominant and recessivemutants
behaved like WT LRP5 in these assays.
Discussion
We sequenced LRP5 in 37 probands who had been re-
ferred with a suspected diagnosis of OPPG. We found
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Figure 3 OPPG-causing missense mutations impair Wnt and Norrin signaling. Fold-induction of luciferase activity in 293T cells expressing
WT or OPPG-causing missense mutants are expressed in combination with Wnt1-v5 (A), Wnt10b (B), and Norrin and Fzd4 (C). Thirty hours
after transfection, ﬁreﬂy luciferase activity was measured and normalized to Renilla luciferase activity. Note that four mutants have no signal
transduction and that three (G404R, D434N, and G610R) have markedly reduced signal transduction (white bars); WT-LRP5 signal transduction
was not inhibited when coexpressed with an OPPG mutant (gray bars), which indicates that the OPPG mutants do not exert a dominant negative
effect (A and B). C, OPPG mutants have reduced ability to transduce Norrin signal. D, Western blot of cell lysates from transfected 293T cells
used in the Wnt1-v5 signal transduction assay shown in panel A, demonstrating comparable expression of WT and OPPG-causing LRP5
receptors. Lysates were separated by SDS-PAGE and were immunodetected with an anti-LRP5/LRP6 antibody, 3801–100 (Biovision). An anti-
tubulin antibody was used to demonstrate that comparable amounts of cell lysates were loaded.
44 likely disease-causing mutations of 64 anticipated
mutant alleles (we anticipated fewer mutant alleles be-
cause several families were consanguineous), for a mu-
tation-detection rate of ∼70%. For those four probands
in whom only one heterozygous change was identiﬁed,
we assume that an undetected second mutation exists in
the other allele. Mutations affecting LRP5 that would
have been missed in our mutation-detection strategy in-
clude exon deletions, intron mutations that affect splic-
ing, coding mutations that could not be PCR ampliﬁed
because of primer annealing-site polymorphisms, andmu-
tations that affect regulatory regions. Another possible
explanation for the presence of only a single mutant
allele is digenic inheritance, which has been observed in
other human diseases (Kajiwara et al. 1994; Katsanis et
al. 2001; Gabriel et al. 2002), including FEVR (Qin et
al. 2005). We sequenced three additional genes, LRP6,
FZD4, and NDP, that have skeletal or ocular ﬁndings
when disrupted in mice (Richter et al. 1998; Holmen et
al. 2004; Xu et al. 2004), but we found no additional
mutations. However, it remains possible that mutant al-
leles of genes encoding other Wnt signaling components,
such as Wnt ligands and other Frizzled receptors, could
cause OPPG in combination with a heterozygous muta-
tion in LRP5.
In addition to ﬁnding likely loss-of-function alleles,
such as those with nonsense and frameshift mutations,
we identiﬁed 20 missense mutations in LRP5. We as-
sume that these are disease-causing because they alter
amino acid residues that are highly conserved across
species. However, this does not prove causality, since
mutations affecting highly conserved amino acid resi-
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Figure 4 FEVR-causing missense mutations variably affect Wnt
and Norrin signaling. Fold-induction of luciferase activity in 293T
cells expressing WT or FEVR-causing missense mutants in combina-
tion with Norrin and Fzd4 (A) or Wnt1-v5 (B). Mutants associated
with autosomal recessive FEVR are underlined. Note that the Y1168H
mutant could not transduceNorrin orWnt signal, andmutants T173M
and E1367K could transduce signal from both ligands (white bars).
Coexpression of WT and FEVR-causing mutant receptors did not in-
terfere with the WT receptor’s ability to transduce Norrin or Wnt-v5
signal (gray bars), which indicates that these mutations do not have
dominant negative effects.
dues can occur without any functional consequence. For
example, residues in the highly conserved catalytic do-
main of Thermus aquaticus DNA polymerase I could
be mutated without disrupting enzymatic activity (Patel
and Loeb 2000). Additionally, two missense mutations,
each affecting a conserved residue, are present on the
same allele in siblings with OPPG (family OP450) (table
1). Therefore, to determine whether missense muta-
tions in LRP5 cause a loss of function, we utilized a
cell-based reporter assay to measure the ability of mu-
tant receptors to transduce Wnt signal. Although we
have not tested all 20 missense mutants, the ﬁrst 7 mu-
tants we did test all had impaired Wnt signal trans-
duction. This result supports the hypothesis that the
skeletal phenotype in OPPG is due to reduction in Wnt
signaling.
The hypothesis that impairment of Wnt signal trans-
duction is speciﬁc to OPPG-causing missense mutations
is supported by studies of LRP5 mutants that cause the
opposite skeletal phenotype, autosomal dominant HBM.
When seven HBM-causing LRP5 mutants were tested
in this assay, none exhibited reduced Wnt signal trans-
duction (Ai et al. 2005). Therefore, this assay should
be useful for determining whether a missense mutation
identiﬁed in a person with OPPG or idiopathic osteo-
porosis is disease causing.
The availability of an allelic series of mutations in
LRP5 that affect Wnt signal transduction enabled us to
ask whether all OPPG mutations affect receptor func-
tion in the same way. By expressing mutant receptors
in transiently transfected cells, we observed that some
mutations impaired receptor trafﬁcking, whereas others
did not. These latter mutations may impair signal trans-
duction at the level of ligand binding, coreceptor inter-
action, or recruitment of cytoplasmic factors. Impor-
tantly, we found no evidence of a dominant negative
effect in any of the mutants tested thus far. Since low
bone mass has been observed in obligate carriers of non-
sense, frameshift, and missense mutations (authors’ un-
published data), functional haploinsufﬁciency appears
to be the common mechanism of mutational effect as-
sociated with isolated osteoporosis.
Within the developing eye, LRP5 may transduce Nor-
rin signal rather than Wnt signal. Mutations in NDP
cause blindness associated with PHPV (Sims 2004),
which has also been observed in patients with OPPG
(Steichen-Gersdorf et al. 1997). A second eye disease,
FEVR, is locus heterogeneous, with mutations identiﬁed
in NDP, FZD4, and LRP5 (Toomes et al. 2004). In
mice and in ex vivo studies these three proteins interact
in a signal transduction pathway (Xu et al. 2004). This
led us to determine whether OPPG-causing mutations
affect Norrin-signal transduction and whether FEVR-
associated mutations affectWnt-signal transduction. All
seven OPPG-causing missense mutants impaired Norrin
signaling (ﬁg. 3C). Surprisingly, there was great vari-
ability in the ability of the FEVR-causing mutant re-
ceptors to transduce Wnt and Norrin signal (ﬁg. 4). For
example, one mutant, Y1168H, which is associated
with autosomal dominant FEVR, was unable to trans-
duce Wnt and Norrin signal, whereas the mutant
R570Q, which is associated with autosomal recessive
FEVR, had residual Wnt- and Norrin-signal transduc-
tion. Another homozygous mutation affecting this res-
idue (R570W) is present in siblings with OPPG (family
OP346) (table 1). We suspect that, when evaluated, the
patients with homozygous R570Q FEVR will have sig-
niﬁcantly reduced BMD. Several other FEVR mutations
had no effect on Wnt or Norrin signaling. We do not
know whether these results imply that these latter mu-
tations are non–disease causing or that the cell-based
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assay is insensitive. The T173M mutation may be an
example of the former possibility, since it was found in
an elderly patient with retinal folds who had no family
history of FEVR (Toomes et al. 2004); additionally, the
mutated residue is not evolutionarily conserved. In sup-
port of the latter possibility are several FEVRmutations
that alter highly conserved residues and the observation
that disease-causing mutations in Norrin have had vari-
able effects on signal transduction in a similar assay (Xu
et al. 2004).
Our results do not help elucidate the mechanism by
which heterozygous mutations in LRP5 cause autoso-
mal dominant FEVR in some families but little eye dis-
ease among the carrier parents and siblings of patients
with OPPG. Because obligate OPPG carriers have not
complained of visual impairment, few eye exams have
been performed (10 parents underwent formal ophthal-
mologic assessment in our study, and only 2 have subtle
evidence of retinal disease [families OP642 and OP482]
[table 1]). This contrasts with FEVR, which had been
considered a highly penetrant disorder (Toomes et al.
2004). Penetrance could be higher in FEVR-affected
families with FZD4 mutations than in families with
LRP5 mutations or could seem to be higher because
family members have undergone studies, such as ﬂuo-
rescein angiography, to detect subtle signs of disease.
Similarly, we do not know which patients with FEVR
may be at increased risk for osteoporosis as are OPPG
carriers, although a recent study reported that ﬁve of
seven patients with FEVR due to LRP5 mutation had
BMD 11 SD below the mean, whereas zero of ﬁve pa-
tients with FEVR due to FZD4 mutation had compa-
rably reduced BMD (Qin et al. 2005).
The results of this study have several practical im-
plications for patients and families suspected of being
affected by OPPG or of having deleterious LRP5 mu-
tations. First, infancy-onset visual loss that is not as-
sociated with vitreoretinal disease seems unlikely to be
due to LRP5, since mutations were not found in the
four probands who lacked vitreoretinal pathology. Sec-
ond, radiographs and quantitative BMD measurements
should be performed in infants and children who have
eye features of OPPG, since skeletal features such as
vertebral compressions may be present but may not be
clinically apparent in young children; early diagnosis of
skeletal disease is important so that affected individuals
can take advantage of emerging therapies for improving
bone strength (Zacharin and Cundy 2000). Third, cog-
nitive problems that are independent of visual impair-
ment occur in only a minority of individuals with OPPG
and do not correlate with the type of LRP5 mutation.
Fourth, most patients with typical features of OPPG have
detectable LRP5 mutations; however, we cannot exclude
locus heterogeneity or digenic inheritance as account-
ing for a minority of cases of OPPG. Last, the ability
to functionally test a mutation’s effect on Wnt- and
possibly Norrin-signal transduction may help determine
whether a variant identiﬁed in patient with OPPG, idio-
pathic osteoporosis, or FEVR is disease causing.
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